7 cm vs. 5 cm Pancreatic Stents for the Prevention of Post-ERCP Pancreatitis in High-risk Patients
Status:
Unknown status
Trial end date:
2020-10-31
Target enrollment:
Participant gender:
Summary
Acute pancreatitis is the most common complication of endoscopic retrograde
cholangiopancreatography (ERCP). The incidence of post-ERCP pancreatitis (PEP) is estimated
to be 10% to 15% in high-risk patients. Current guidelines recommend using pancreatic duct
stent (PDS) for PEP prevention in high-risk patients, but it is not clear whether stent
length will affect the effect of PEP prevention. The longer PDS will remain in the pancreatic
duct for a longer period of time, thereby ensuring prolonged decompression with subsequent
lowering of the risk for PEP. Findings from two retrospective studies showed that longer PDS
was more effective in reducing the risk of post-ERCP hyperamylasemia and the frequency of PEP
compared with the shorter PDS. We conducted this trial to test whether 7cm PDS was superior
to 5cm PDS in PEP prevention in high-risk patients.
Phase:
N/A
Details
Lead Sponsor:
Air Force Military Medical University, China Fourth Military Medical University